LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
F. Joly Lobbedez, Alexandra Léary, Isabelle Laure Ray-Coquard, Bernard Asselain, Manuel Rodrigues, Laurence Gladieff, Fernando Bazán, Sophie Abadie Lacourtoisie, Coriolan Lebreton, L. Bengrine Lefevre, Karen Leroy, Richard Leman, P. Fournel, R. Largillier, Frédèric Selle, Jean‐Sébastien Frenel, Y. Fernandez, Cyril Foa, Benoît You, Jérôme Alexandre
Topics & Concepts
MedicineInternal medicineClinical endpointOlaparibPlaceboPopulationResponse Evaluation Criteria in Solid TumorsOncologyPARP inhibitorEndometrial cancerProgression-free survivalRandomized controlled trialMaintenance therapyEverolimusCancerUrologyPhases of clinical researchChemotherapyPathologyAlternative medicineChemistryPoly ADP ribose polymerasePolymeraseGeneBiochemistryEnvironmental healthPARP inhibition in cancer therapyProstate Cancer Treatment and ResearchCancer Genomics and Diagnostics